According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...
According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...
Zacks Small Cap Research on MSN49m
AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment MeasuresAEMD READ THE FULL AEMD RESEARCH REPORT Patient enrollments begin for AEMD’s basket oncology trial Aethlon Medical (NASDAQ:AEMD) announced FY 2Q results and provided a business update yesterday. The ...
Keytruda’s main rival in the immuno-oncology space, BMS’ Opdivo (nivolumab), is predicted to come in fourth place, seemingly placing Keytruda as the ultimate winner in what has been one of the ...
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...
It's been spectacularly successful, but with $17 billion-a-year Keytruda (pembrolizumab) now accounting for more than a third of its total sales there has been pressure on the company to diversify.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback